9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Estimated reading time: < 1 min

Condition: Melanoma

Estimated Enrollment: 87

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Determine the safety and tolerability profile of XmAb20717,  ,  ,

Interventions: XmAb20717,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Sequential Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: December 2020

Completion Date: March 2021

Last  Posted Date: May 1, 2019

Location: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03517488

Was this article helpful?
Dislike 0